The transfer of adaptive immunity to CMV during hematopoietic stem cell transplantation is dependent on the specificity and phenotype of CMV-specific T cells in the donor.

The successful reconstitution of adaptive immunity to human cytomegalovirus (CMV) in hematopoietic stem cell transplantation (HSCT) recipients is central to the reduction of viral reactivation-related morbidity and mortality. Here, we characterized the magnitude, specificity, phenotype, function, and clonotypic composition of CMV-specific T-cell responses in 18 donor-recipient pairs both before and after HSCT. The principal findings were: (1) the specificity of CMV-specific T-cell responses in the recipient after HSCT mirrors that in the donor; (2) the maintenance of these targeting patterns reflects the transfer of epitope-specific T-cell clonotypes from donor to recipient; (3) less differentiated CD27(+)CD57(-) CMV-specific memory T cells are more likely to persist in the recipient after HSCT compared with more terminally differentiated CD27(-) CD57(+) CMV-specific memory T cells; (4) the presence of greater numbers of less differentiated CD8(+) CMV-specific T cells in the donor appears to confer protection against viral reactivation in the recipient after HSCT; and (5) CMV-specific T cells acquire a more differentiated phenotype and a restricted functional profile after HSCT. Overall, these findings define the immunologic factors that influence the successful adoptive transfer of antigen-specific T-cell immunity during HSCT, which enables the identification of recipients at particular risk of CMV reactivation after HSCT.

[1]  U. Andersson,et al.  Effects of FK506 and cyclosporin A on cytokine production studied in vitro at a single-cell level. , 1992, Immunology.

[2]  Y. Ilan,et al.  Adoptive transfer of immunity to hepatitis B virus in mice by bone marrow transplantation from immune donors , 1993, Hepatology.

[3]  S. Riddell,et al.  Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. , 1995, The New England journal of medicine.

[4]  P. Duffey,et al.  Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor , 1995, The Lancet.

[5]  D. Longo,et al.  Active immunization of murine allogeneic bone marrow transplant donors with B-cell tumor-derived idiotype: a strategy for enhancing the specific antitumor effect of marrow grafts. , 1996, Blood.

[6]  S. Ikehara,et al.  Transfer of autoimmune thyroiditis and resolution of palmoplantar pustular psoriasis following allogeneic bone marrow transplantation , 1997, Bone Marrow Transplantation.

[7]  A. Gratwohl,et al.  Celiac disease transmitted by allogeneic non-T cell-depleted bone marrow transplantation , 1997, Bone Marrow Transplantation.

[8]  S. Ikehara.  Bone Marrow Transplantation for Autoimmune Diseases , 1998, Acta Haematologica.

[9]  H. Kolb,et al.  Transfer of diabetes type 1 by bone-marrow transplantation , 1998, The Lancet.

[10]  D. Srivastava,et al.  Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. , 1998, Blood.

[11]  D. Srivastava,et al.  Infusion of Cytotoxic T Cells for the Prevention and Treatment of Epstein-Barr Virus–Induced Lymphoma in Allogeneic Transplant Recipients , 1998 .

[12]  J. Dick,et al.  CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[13]  D. Strunk,et al.  Adoptive transfer of vitiligo after allogeneic bone marrow transplantation for non-Hodgkin's lymphoma , 2000, The Lancet.

[14]  R. Koup,et al.  Putative Immunodominant Human Immunodeficiency Virus-Specific CD8+ T-Cell Responses Cannot Be Predicted by Major Histocompatibility Complex Class I Haplotype , 2000, Journal of Virology.

[15]  T. Schumacher,et al.  Differentiation of cytomegalovirus-specific CD8(+) T cells in healthy and immunosuppressed virus carriers. , 2001, Blood.

[16]  C. Craddock,et al.  Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. , 2001, Blood.

[17]  C. Tournay,et al.  Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. , 2001, Blood.

[18]  D. Taub,et al.  Effect of rapamycin on the cyclosporin A-resistant CD28-mediated costimulatory pathway. , 2002, Blood.

[19]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[20]  Daniel C. Douek,et al.  A Novel Approach to the Analysis of Specificity, Clonality, and Frequency of HIV-Specific T Cell Responses Reveals a Potential Mechanism for Control of Viral Escape1 , 2002, The Journal of Immunology.

[21]  John E Bennett,et al.  Clinical trial of quantitative real-time polymerase chain reaction for detection of cytomegalovirus in peripheral blood of allogeneic hematopoietic stem-cell transplant recipients. , 2003, The Journal of infectious diseases.

[22]  R. Koup,et al.  Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. , 2003, Journal of immunological methods.

[23]  H. Kirchner,et al.  Individual variability in cyclosporin A sensitivity: the assessment of functional measures on CD28-mediated costimulation of human whole blood T lymphocytes. , 2003, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[24]  Nitin J. Karandikar,et al.  Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. , 2003, Blood.

[25]  P. Moss,et al.  Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines , 2003, The Lancet.

[26]  Rustom Antia,et al.  Lineage relationship and protective immunity of memory CD8 T cell subsets , 2003, Nature Immunology.

[27]  M. Wills,et al.  Human cytomegalovirus-specific immunity following haemopoietic stem cell transplantation. , 2003, Blood reviews.

[28]  L. Picker,et al.  Mapping T cell epitopes by flow cytometry. , 2003, Methods.

[29]  R. Marcus,et al.  Late diversification in the clonal composition of human cytomegalovirus-specific CD8+ T cells following allogeneic hemopoietic stem cell transplantation. , 2003, Blood.

[30]  Richard A Koup,et al.  T cell receptor recognition motifs govern immune escape patterns in acute SIV infection. , 2004, Immunity.

[31]  Marie-Paule Lefranc,et al.  IMGT, The International ImMunoGeneTics Information System, http://imgt.cines.fr. , 2004, Methods in molecular biology.

[32]  S. Mackinnon,et al.  Augmentation of virus-specific immunity after hematopoietic stem cell transplantation by adoptive T-cell therapy. , 2004, Human immunology.

[33]  Antonio Lanzavecchia,et al.  Central memory and effector memory T cell subsets: function, generation, and maintenance. , 2004, Annual review of immunology.

[34]  J. Zaia,et al.  Assessment of cellular immunity to human cytomegalovirus in recipients of allogeneic stem cell transplants. , 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[35]  H. Heslop,et al.  Cytotoxic T Lymphocyte Therapy for Epstein-Barr Virus+ Hodgkin's Disease , 2004, The Journal of experimental medicine.

[36]  S. Migueles,et al.  Avidity for antigen shapes clonal dominance in CD8+ T cell populations specific for persistent DNA viruses , 2005, The Journal of experimental medicine.

[37]  Louis J. Picker,et al.  Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects , 2005, The Journal of experimental medicine.

[38]  S. Rosenberg,et al.  Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  C. Craddock,et al.  Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA–peptide tetramers , 2005, The Journal of experimental medicine.

[40]  T. Waldmann,et al.  Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[41]  M. Betts,et al.  Polyfunctional analysis of human t cell responses: importance in vaccine immunogenicity and natural infection , 2006, Springer Seminars in Immunopathology.

[42]  D. Lilleri,et al.  Prospective simultaneous quantification of human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in young recipients of allogeneic hematopoietic stem cell transplants. , 2006, Blood.

[43]  R. Koup,et al.  Acquisition of direct antiviral effector functions by CMV-specific CD4+ T lymphocytes with cellular maturation , 2006, The Journal of experimental medicine.

[44]  S. Fischer,et al.  Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. , 2006, Blood.

[45]  D. Douek,et al.  The clonal composition of human CD4+CD25+Foxp3+ cells determined by a comprehensive DNA-based multiplex PCR for TCRB gene rearrangements. , 2007, Journal of immunological methods.

[46]  L. Picker,et al.  Induction and Evolution of Cytomegalovirus-Specific CD4+ T Cell Clonotypes in Rhesus Macaques1 , 2008, The Journal of Immunology.

[47]  Mike Gough,et al.  Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. , 2008, The Journal of clinical investigation.

[48]  D. Douek,et al.  Regulatory T-cell depletion does not prevent emergence of new CD25+ FOXP3+ lymphocytes after antigen stimulation in culture. , 2008, Cytotherapy.